Stephen K. Tahir

12.4k citations

35 papers · 3.3k indexed · 1 hit paper · h-index 22

Molecular Biology top 5%
Oncology top 5%
Immunology top 10%
Genetics top 5%
Hematology top 5%

Co-authors: Saul H. Rosenberg Christin Tse Haichao Zhang Stephen W. Fesik Xiufen Yang Mark G. Anderson Steven W. Elmore Sha Jin
Topics: Cell death mechanisms and regulation (13 papers)Chronic Lymphocytic Leukemia Research (6 papers)Microtubule and mitosis dynamics (5 papers)
Cited by: Oncology Molecular Biology Genetics
Journals: Journal of Biological Chemistry Blood Cancer Research
Partner nations: United States United Kingdom Canada

In The Last Decade

Stephen K. Tahir

33 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

2008 1.5k citations Christin Tse, Alexander R. Shoemaker et al. Cancer Research profile →

Peers

Countries citing papers authored by Stephen K. Tahir

Since Specialization

Citations

This map shows the geographic impact of Stephen K. Tahir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen K. Tahir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen K. Tahir more than expected).

Fields of papers citing papers by Stephen K. Tahir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen K. Tahir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen K. Tahir. The network helps show where Stephen K. Tahir may publish in the future.

Co-authorship network of co-authors of Stephen K. Tahir

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen K. Tahir. A scholar is included among the top collaborators of Stephen K. Tahir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen K. Tahir. Stephen K. Tahir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer immunotherapy 2025 ·Cell Death and Disease ·(unknown),Kelly Doyle,Julie J. Purkal,Cara L. Hrusch,Ryan Duggan,Erwin R. Boghaert,Andrew J. Souers,Darren C. Phillips,Stephen K. Tahir	0
2	Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia 2023 ·Blood ·Stephen K. Tahir,Emiliano Calvo,Benedito A. Carneiro,Junichiro Yuda,Aditya Shreenivas,Mojca Jongen‐Lavrencic,Eelke Gort,Kenichi Ishizawa,Daniel Morillo,(unknown),Morey L. Smith,Cheng Dong,Monica Motwani,David Sharon,Tamar Uziel,Dimple Modi,Fritz G. Buchanan,Susan E. Morgan-Lappe,Bruno C. Medeiros,Darren C. Phillips	9
3	Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors 2021 ·Cancer Research ·Darren C. Phillips,Fritz G. Buchanan,Dong Cheng,Larry R. Solomon,Xiao Yu,John Xue,Stephen K. Tahir,Morey L. Smith,Haichao Zhang,D. L. Widomski,Vivek C. Abraham,Nan Xu,Zhihong Liu,Li Zhou,Enrico L. DiGiammarino,Xin Lü,Nandini Rudra-Ganguly,Bruce A. Trela,Susan E. Morgan-Lappe	32
4	Quantification of BCL-2 Family Members by Flow Cytometry 2018 ·Methods in molecular biology ·Morey L. Smith,Stephen K. Tahir	1
5	Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors 2017 ·Molecular Cancer Therapeutics ·Lloyd T. Lam,Xiaoyu Lin,Emily J. Faivre,Ziping Yang,Xiaoli Huang,Denise M. Wilcox,Richard J. Bellin,Sha Jin,Stephen K. Tahir,Michael J. Mitten,(unknown),Anahita Bhathena,Warren M. Kati,Daniel H. Albert,Yu Shen,Tamar Uziel	55
6	Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors 2017 ·Blood ·Stephen K. Tahir,Morey L. Smith,Larry R. Solomon,Haichao Zhang,John Xue,Xiao Yu,Dong Cheng,(unknown),Susan E. Morgan-Lappe,Darren C. Phillips	8
7	Potential mechanisms of resistance to venetoclax and strategies to circumvent it 2017 ·BMC Cancer ·Stephen K. Tahir,Morey L. Smith,Paul Hessler,(unknown),Kenneth B. Idler,Chang H. Park,Joel Johansson,Lloyd T. Lam	142
8	Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer 2015 ·Molecular Cancer ·Haichao Zhang,John Xue,Paul Hessler,Stephen K. Tahir,Jun Chen,Sha Jin,Andrew J. Souers,Joel Johansson,Lloyd T. Lam	43
9	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo 2011 ·Molecular Cancer Therapeutics ·Jun Chen,Sha Jin,(unknown),Xiaoli Huang,Bernard A. Liu,Michael J. Mitten,Paul Nimmer,Xiaoyu Lin,Morey L. Smith,Yu Shen,Alexander R. Shoemaker,Stephen K. Tahir,Haichao Zhang,Scott Ackler,Saul H. Rosenberg,Heather Maecker,Deepak Sampath,Joel Johansson,Chris Tse,Steven W. Elmore	119
10	Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines 2010 ·Molecular Cancer Therapeutics ·Stephen K. Tahir,John Wass,Mary K. Joseph,Viswanath Devanarayan,Paul Hessler,Haichao Zhang,Steve W. Elmore,Paul E. Kroeger,Christin Tse,Saul H. Rosenberg,Mark G. Anderson	59
11	The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo 2010 ·Cancer Chemotherapy and Pharmacology ·Scott Ackler,Michael J. Mitten,Kelly Foster,Anatol Oleksijew,Marion Refici,Stephen K. Tahir,Xiao Yu,Christin Tse,David J. Frost,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore,Alexander R. Shoemaker	100
12	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitorbreakdown → 2008 ·Cancer Research ·Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa Roberts,Stephen K. Tahir,Xiao Yu,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore	1513
13	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 2007 ·Cancer Research ·Stephen K. Tahir,Xiufen Yang,Mark G. Anderson,Susan E. Morgan-Lappe,Aparna V. Sarthy,Jun Chen,Robert B. Warner,Shi‐Chung Ng,Stephen W. Fesik,Steve W. Elmore,Saul H. Rosenberg,Christin Tse	250
14	Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains 2007 ·Molecular Cancer Research ·Edward T. Olejniczak,Charles Van Sant,Mark G. Anderson,Gang Greg Wang,Stephen K. Tahir,Guido Sauter,Rick Lesniewski,Dimitri Semizarov	53
15	Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells 2002 ·Journal of Biological Chemistry ·Jun Chen,Sha Jin,Stephen K. Tahir,Haichao Zhang,Xuesong Liu,Aparna V. Sarthy,Thomas McGonigal,Zhihong Liu,Saul H. Rosenberg,Shi‐Chung Ng	101
16	Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. 2001 ·PubMed ·Yan Luo,(unknown),Mary K. Joseph,(unknown),Christopher Butler,Stephen K. Tahir,Edward K. Han,Shi‐Chung Ng,Jean M. Severin,Earl J. Gubbins,Regina M. Reilly,(unknown),Robert L. Simmer,(unknown),Vincent L. Giranda	28
17	Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth 2000 ·Neoplasia ·Jun Chen,Wei Wu,Stephen K. Tahir,Paul E. Kroeger,Saul H. Rosenberg,Lex M. Cowsert,Frank Bennett,Stanisław Krajewski,Maryla Krajewska,Kate Welsh,John C. Reed,Shi‐Chung Ng	169
18	Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements 1999 ·Bioorganic & Medicinal Chemistry Letters ·Shen Wang,Stephen A. Fakhoury,(unknown),Kenneth J. Henry,(unknown),Haichao Zhang,Jerry D. Cohen,Robert R. Warner,(unknown),Sajeev Cherian,Stephen K. Tahir,Peter Kovar,Joy Bauch,Shi‐Chung Ng,Kennan Marsh,Hing L. Sham,Saul H. Rosenberg	7
19	CANNABINOID ENANTIOMER ACTION ON THE CYTOARCHITECTURE 1996 ·Cell Biology International ·(unknown),Stephen K. Tahir,Raphael Mechoulam,Selma Zimmerman,Arthur M. Zimmerman	25
20	Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells 1992 ·Biochemistry and Cell Biology ·Stephen K. Tahir,Judy Trogadis,John K. Stevens,Arthur M. Zimmerman	54

About Stephen K. Tahir

Stephen K. Tahir is a scholar working on Hematology, Genetics and Oncology, having authored 35 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Microtubule and mitosis dynamics (5 papers). The work is most often cited by research in Oncology (980 citations), Molecular Biology (2.4k citations) and Genetics (344 citations). Stephen K. Tahir has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Saul H. Rosenberg, Christin Tse, Haichao Zhang, Stephen W. Fesik, Xiufen Yang, Mark G. Anderson, Steven W. Elmore, Sha Jin, Alexander R. Shoemaker and Paul Nimmer. Their work appears in journals such as Journal of Biological Chemistry, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact